Scienture Holdings Inc (SCNX)

$1.57 -1.03 (-39.62%)
Market Cap 36.47M
Revenue (ttm) 140,000.00
Net Income (ttm) 9.07M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 6,478.57%
Debt to Equity Ratio 0.01
Volume 76,539,805
Avg Vol 20,269,240
Day's Range N/A - N/A
Shares Out 23.23M
Stochastic %K 52%
Beta 3.11
Analysts Strong Buy
Price Target N/A

Company Profile

Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company operates through Integra and Scienture segments. The Integra segment engages in the wholesale and sale of licensed pharmaceutical brand, generic, and non-drug products. The Scienture segment researches and develops branded pharmaceutical products. The company develops SCN...

Industry: Pharmaceutical Retailers
Sector: Healthcare
Phone: 800 261 0281
Address:
6308 Benjamin Rd, Suite 708, Tampa, United States
Oronero
Oronero Oct. 27 at 12:58 PM
$SCNX Essential lifesaving medicine...#huge
0 · Reply
ChasingGreenCandle
ChasingGreenCandle Oct. 27 at 12:57 PM
$SCNX from my estimats and quantitative data the market open for this stock it will be above $1.365
0 · Reply
Muhammad7
Muhammad7 Oct. 27 at 12:52 PM
$SCNX dumb drop
0 · Reply
bassett
bassett Oct. 27 at 12:49 PM
$SCNX (SCNX) Dead. $CODX I did rightnow 15% profit in 20second
0 · Reply
ChasingGreenCandle
ChasingGreenCandle Oct. 27 at 12:40 PM
$SCNX guys stop making bets and think and do your own research. The shorts don't know what they are shorting also. This company released a new product.(losartan) In a US Market there are $256 million annual prescriptions. This product is a need for the patients who cannot swallow tablets, such as children over six and elderly adults with dysphagia. This medication dies not require refrigeration and has a 24 months shelf life at room temperature. The stock drops because it was a share dilution and the shorts profited. The capital rise it was a must. You can check my previous post also. DO YOUR OWN DD AND STOP RELY ON OTHERS.
0 · Reply
bassett
bassett Oct. 27 at 12:32 PM
$SCNX (SCNX) Still red flag. RECT stock of the day i make 27% profit
0 · Reply
Watsonwestie
Watsonwestie Oct. 27 at 12:30 PM
$SCNX lol. See you at 2.00
0 · Reply
JackCampbell
JackCampbell Oct. 27 at 12:27 PM
$SCNX expect exclusive requests and agreements for the distribution of Arbli in other global regions anytime now. Scienture would receive a high upfront payment and percentage of net sales with beginning sales. Further collaborations will enable access to Arbli for patients wordwide in very short time period.
0 · Reply
ChasingGreenCandle
ChasingGreenCandle Oct. 27 at 12:23 PM
$SCNX guys I want to inform you about the following. The share dilution raport: 30/September 21.93 million shares 27/October 34.47 million shares The share dilution was completed. Curent Cash Estimate $14.35 million. So they have cash to operate normaly for a while. They released a new product and the cash will come soon to sustain the business.
1 · Reply
invbond
invbond Oct. 27 at 12:18 PM
$SCNX is holding up well and well above $0.50 level a few days ago. We will be back over to $2.0 again Keep an eye on $VIVK - Squeeze alert ( like SCNX) could pop it back to Friday's high of ~$0.50 and Squeeze it over to $1.X+ Has ~$250M in assets and just closed a $40M CF.
1 · Reply
Latest News on SCNX
SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)

Oct 23, 2025, 8:05 AM EDT - 4 days ago

SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)

SCIENTURE'S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers

Oct 16, 2025, 9:00 AM EDT - 11 days ago

SCIENTURE'S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers

Wellgistics Health Announces Executive Management and Board Changes

Oct 13, 2025, 8:00 AM EDT - 14 days ago

Wellgistics Health Announces Executive Management and Board Changes

WGRX

SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market

Sep 16, 2025, 8:05 AM EDT - 5 weeks ago

SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market

Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock

Aug 14, 2025, 9:00 AM EDT - 2 months ago

Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock

SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.

Aug 13, 2025, 8:05 AM EDT - 2 months ago

SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.

Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding

Jul 24, 2025, 5:12 PM EDT - 3 months ago

Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding

Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements

Jul 16, 2025, 8:15 AM EDT - 3 months ago

Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements

Scienture Holdings Announces Cancelation of ELOC

Jun 17, 2025, 8:05 AM EDT - 4 months ago

Scienture Holdings Announces Cancelation of ELOC

Wellgistics Health Strengthens Executive Team and Board with Strategic Appointments to Accelerate Scale and Drive Shareholder Value

May 28, 2025, 7:45 AM EDT - 5 months ago

Wellgistics Health Strengthens Executive Team and Board with Strategic Appointments to Accelerate Scale and Drive Shareholder Value

WGRX

SCIENTURE Announces Executive Leadership Transition

May 22, 2025, 8:05 AM EDT - 5 months ago

SCIENTURE Announces Executive Leadership Transition

SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL.

May 19, 2025, 8:05 AM EDT - 5 months ago

SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL.

SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.

Apr 22, 2025, 8:05 AM EDT - 6 months ago

SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.

SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.

Apr 8, 2025, 8:05 AM EDT - 7 months ago

SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.

Scienture Holdings, Inc. Issues Annual Letter to Shareholders

Apr 3, 2025, 8:26 AM EDT - 7 months ago

Scienture Holdings, Inc. Issues Annual Letter to Shareholders

SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization

Mar 25, 2025, 8:05 AM EDT - 7 months ago

SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization

Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days

Mar 19, 2025, 8:05 AM EDT - 7 months ago

Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days

SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.

Mar 18, 2025, 8:05 AM EDT - 7 months ago

SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.

SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.

Mar 6, 2025, 7:40 AM EST - 8 months ago

SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.

Scienture Holdings, Inc. Announces Dr. Narasimhan Mani's Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics

Jan 21, 2025, 8:05 AM EST - 9 months ago

Scienture Holdings, Inc. Announces Dr. Narasimhan Mani's Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics

Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025

Dec 17, 2024, 8:05 AM EST - 11 months ago

Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025

Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041

Dec 10, 2024, 8:05 AM EST - 11 months ago

Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX”

Sep 24, 2024, 8:01 AM EDT - 1 year ago

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX”

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc.

Sep 20, 2024, 11:59 AM EDT - 1 year ago

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc.

TRxADE Health, Inc. Announces New Addition and Changes to Scienture, LLC's Executive Leadership Team

Aug 5, 2024, 8:01 AM EDT - 1 year ago

TRxADE Health, Inc. Announces New Addition and Changes to Scienture, LLC's Executive Leadership Team

TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million

Jul 26, 2024, 8:01 AM EDT - 1 year ago

TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million

TRxADE Health, Inc. Announces Special Cash Dividend

Jul 9, 2024, 8:05 AM EDT - 1 year ago

TRxADE Health, Inc. Announces Special Cash Dividend

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

May 29, 2024, 4:05 PM EDT - 1 year ago

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

Apr 23, 2024, 4:05 PM EDT - 1 year ago

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

Trxade health, Inc files its 3Q 10Q

Jan 17, 2024, 9:07 AM EST - 1 year ago

Trxade health, Inc files its 3Q 10Q

TRxADE Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q.

Nov 29, 2023, 6:13 PM EST - 2 years ago

TRxADE Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q.

TrxADE Health, Inc. affirms its commitment to the pharmaceutical space via its subsidiary Trxade, Inc. which operates the pharmaceutical marketplace and added more members in the third quarter of 2023.

Oct 17, 2023, 8:05 AM EDT - 2 years ago

TrxADE Health, Inc. affirms its commitment to the pharmaceutical space via its subsidiary Trxade, Inc. which operates the pharmaceutical marketplace and added more members in the third quarter of 2023.

Superlatus Announces Distribution Partnership with North America's Leading Wholesale Distributor and Expanded Points of Retail Sales

Oct 12, 2023, 8:05 AM EDT - 2 years ago

Superlatus Announces Distribution Partnership with North America's Leading Wholesale Distributor and Expanded Points of Retail Sales

Superlatus, Newly Merged with TRxADE HEALTH, Acquires the assets of Spero Foods, a plant-based tech company Disrupting the Dairy and Egg Industry.

Oct 4, 2023, 8:05 AM EDT - 2 years ago

Superlatus, Newly Merged with TRxADE HEALTH, Acquires the assets of Spero Foods, a plant-based tech company Disrupting the Dairy and Egg Industry.

TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, Is Gearing Up To Make Big Splashes In the $151 Billion Snacks Industry with its Acquisition of The Urgent Company Inc.

Sep 7, 2023, 9:00 AM EDT - 2 years ago

TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, Is Gearing Up To Make Big Splashes In the $151 Billion Snacks Industry with its Acquisition of The Urgent Company Inc.

TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, To Acquire The Urgent Company to Expand its Reach In The Sustainable Foods Market

Sep 6, 2023, 9:45 AM EDT - 2 years ago

TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, To Acquire The Urgent Company to Expand its Reach In The Sustainable Foods Market

Superlatus Innovates $151 Billion US Snacking Market with Pulse-Based Protein Twists Under the Brave Robot Brand

Aug 24, 2023, 8:05 AM EDT - 2 years ago

Superlatus Innovates $151 Billion US Snacking Market with Pulse-Based Protein Twists Under the Brave Robot Brand

Superlatus, Newly Merged with TRxADE HEALTH, Agrees to Acquire The Urgent Company, Inc. and its portfolio of Consumer Brands from Perfect Day, Inc.

Aug 22, 2023, 8:05 AM EDT - 2 years ago

Superlatus, Newly Merged with TRxADE HEALTH, Agrees to Acquire The Urgent Company, Inc. and its portfolio of Consumer Brands from Perfect Day, Inc.

TRxADE HEALTH, Inc. Announces Extension of Form 10-Q Filing

Aug 14, 2023, 10:25 AM EDT - 2 years ago

TRxADE HEALTH, Inc. Announces Extension of Form 10-Q Filing

Newly merged Entity Superlatus, Inc with Trxade Health, Inc. Appoints Leading CPG Management Team

Aug 3, 2023, 9:05 AM EDT - 2 years ago

Newly merged Entity Superlatus, Inc with Trxade Health, Inc. Appoints Leading CPG Management Team

TRxADE HEALTH, INC. to Report Q2 2023 Financial Results on Monday, August 14th at 6:00 p.m.

Jul 31, 2023, 4:15 PM EDT - 2 years ago

TRxADE HEALTH, INC. to Report Q2 2023 Financial Results on Monday, August 14th at 6:00 p.m.

TRxADE HEALTH, Inc. Announces Closing of Acquisition of Superlatus, Inc.

Jul 31, 2023, 8:35 AM EDT - 2 years ago

TRxADE HEALTH, Inc. Announces Closing of Acquisition of Superlatus, Inc.

TRxADE HEALTH, Inc. Amends Definitive Merger Agreement with Superlatus, Inc.

Jul 14, 2023, 4:30 PM EDT - 2 years ago

TRxADE HEALTH, Inc. Amends Definitive Merger Agreement with Superlatus, Inc.

Superlatus, Inc. and TRxADE HEALTH, Inc. Sign Definitive Merger Agreement to Create a Global Strategic Platform for Food and Healthy Snack Marketplace and Distribution

Jun 30, 2023, 8:05 AM EDT - 2 years ago

Superlatus, Inc. and TRxADE HEALTH, Inc. Sign Definitive Merger Agreement to Create a Global Strategic Platform for Food and Healthy Snack Marketplace and Distribution

TRxADE HEALTH, Inc. Issues Correction to Press Release Announcing its Anticipated Combination with Superlatus, Inc. (Correction Notice)

Jun 23, 2023, 4:40 PM EDT - 2 years ago

TRxADE HEALTH, Inc. Issues Correction to Press Release Announcing its Anticipated Combination with Superlatus, Inc. (Correction Notice)

EAT WELL GROUP TO SELL SAPIENTIA FOR USD $10 MILLION IN NASDAQ MERGER WITH MEDS & SUPERLATUS FOODS

Jun 23, 2023, 3:00 PM EDT - 2 years ago

EAT WELL GROUP TO SELL SAPIENTIA FOR USD $10 MILLION IN NASDAQ MERGER WITH MEDS & SUPERLATUS FOODS

Superlatus, Inc. to Combine with TRxADE HEALTH, Inc., to Create a Global Food Consolidation Platform

Jun 23, 2023, 8:05 AM EDT - 2 years ago

Superlatus, Inc. to Combine with TRxADE HEALTH, Inc., to Create a Global Food Consolidation Platform

TRxADE Health, Inc.'s Board of Directors Approves Reverse Stock Split

Jun 21, 2023, 12:36 PM EDT - 2 years ago

TRxADE Health, Inc.'s Board of Directors Approves Reverse Stock Split

TRxADE HEALTH, Inc. (MEDS) Q1 2023 Earnings Call Transcript

May 15, 2023, 10:30 PM EDT - 2 years ago

TRxADE HEALTH, Inc. (MEDS) Q1 2023 Earnings Call Transcript

TRxADE HEALTH Reports First Quarter Gross Margin of 69% and Q1 2023 Financial Results

May 15, 2023, 5:00 PM EDT - 2 years ago

TRxADE HEALTH Reports First Quarter Gross Margin of 69% and Q1 2023 Financial Results

Oronero
Oronero Oct. 27 at 12:58 PM
$SCNX Essential lifesaving medicine...#huge
0 · Reply
ChasingGreenCandle
ChasingGreenCandle Oct. 27 at 12:57 PM
$SCNX from my estimats and quantitative data the market open for this stock it will be above $1.365
0 · Reply
Muhammad7
Muhammad7 Oct. 27 at 12:52 PM
$SCNX dumb drop
0 · Reply
bassett
bassett Oct. 27 at 12:49 PM
$SCNX (SCNX) Dead. $CODX I did rightnow 15% profit in 20second
0 · Reply
ChasingGreenCandle
ChasingGreenCandle Oct. 27 at 12:40 PM
$SCNX guys stop making bets and think and do your own research. The shorts don't know what they are shorting also. This company released a new product.(losartan) In a US Market there are $256 million annual prescriptions. This product is a need for the patients who cannot swallow tablets, such as children over six and elderly adults with dysphagia. This medication dies not require refrigeration and has a 24 months shelf life at room temperature. The stock drops because it was a share dilution and the shorts profited. The capital rise it was a must. You can check my previous post also. DO YOUR OWN DD AND STOP RELY ON OTHERS.
0 · Reply
bassett
bassett Oct. 27 at 12:32 PM
$SCNX (SCNX) Still red flag. RECT stock of the day i make 27% profit
0 · Reply
Watsonwestie
Watsonwestie Oct. 27 at 12:30 PM
$SCNX lol. See you at 2.00
0 · Reply
JackCampbell
JackCampbell Oct. 27 at 12:27 PM
$SCNX expect exclusive requests and agreements for the distribution of Arbli in other global regions anytime now. Scienture would receive a high upfront payment and percentage of net sales with beginning sales. Further collaborations will enable access to Arbli for patients wordwide in very short time period.
0 · Reply
ChasingGreenCandle
ChasingGreenCandle Oct. 27 at 12:23 PM
$SCNX guys I want to inform you about the following. The share dilution raport: 30/September 21.93 million shares 27/October 34.47 million shares The share dilution was completed. Curent Cash Estimate $14.35 million. So they have cash to operate normaly for a while. They released a new product and the cash will come soon to sustain the business.
1 · Reply
invbond
invbond Oct. 27 at 12:18 PM
$SCNX is holding up well and well above $0.50 level a few days ago. We will be back over to $2.0 again Keep an eye on $VIVK - Squeeze alert ( like SCNX) could pop it back to Friday's high of ~$0.50 and Squeeze it over to $1.X+ Has ~$250M in assets and just closed a $40M CF.
1 · Reply
ChasingGreenCandle
ChasingGreenCandle Oct. 27 at 12:13 PM
$SCNX the share dilution was completed. Algo traded 1.2 million shares in 1 minute from $1.23 to $1.50. If one of this level is breaked we will see the continuation of the stock. I analyze all the move with my python code from time and sales. The only way to see behind the scenes is to fight back with your own tools.
0 · Reply
KryptonianTrader
KryptonianTrader Oct. 27 at 12:08 PM
$SCNX RISE AND PHUCK THE SHORTS…
0 · Reply
Jojomightknow
Jojomightknow Oct. 27 at 12:04 PM
$SCNX share count updated. Diluted from 20.75 to 31.975
1 · Reply
PlayedOutNCruel
PlayedOutNCruel Oct. 27 at 12:01 PM
$SCNX the aliens must be running the show today !!!
1 · Reply
bassett
bassett Oct. 27 at 12:00 PM
$SCNX (SCNX) currently exhibits weak market fundamentals. Profitability ratios are alarmingly negative, with EBIT and EBITDA margins at -15614.4% and -14074.5% respectively, underscoring significant operational inefficiencies. Revenues have seen declines over the 3-year and 5-year periods by -77.63% and -60.18%, a concerning trajectory.a potential red flag for investors.
0 · Reply
igniteyourpassion
igniteyourpassion Oct. 27 at 11:49 AM
$SCNX https://www.timothysykes.com/news/scientureholdingsinc-scnx-news-2025_10_26/
0 · Reply
bassett
bassett Oct. 27 at 11:45 AM
$SCNX Just short squeez Short seller cover their shares, after will drop to 0.8
0 · Reply
grindlife_98
grindlife_98 Oct. 27 at 11:45 AM
$SCNX Banggg🤝🏼🔥
0 · Reply
Limer_814
Limer_814 Oct. 27 at 11:45 AM
$SCNX almost sure the offering is closed already at or above 2.60 last week ..
0 · Reply
Limer_814
Limer_814 Oct. 27 at 11:42 AM
$SCNX Red to Green will be a glorious move
0 · Reply
JackCampbell
JackCampbell Oct. 27 at 11:41 AM
$SCNX ++++BREAKING NEWS++++NOW WITH START OF COMMERCIAL SALES OF ARBLI™+++++ Arbli™ is the first and only oral liquid formulation of losartan approved by the U.S. FDA. Arbli™ comes in a 165 mL bottle as a peppermint flavored suspension that does not require refrigeration and has been approved for a shelf life of 24 months from the date of manufacture when stored at room temperature. BTW: it´s the best in world drug as there is no other liquid formulation approved anywhere!
0 · Reply
TheRealStockRocket
TheRealStockRocket Oct. 27 at 11:10 AM
$RELI If your playing $ASST like me....you need to look at $RELI as well. *See Below. $RELI has a tiny 3M float vs 270M float in $ASST. $ASST has hype & momo... $RELI is going to be a monster low floater play accumulating digital assets from Bitcoin, XRP, Ethereum etc. to coincide with the core business to scale and is strategizing to revolutionize the insurance industry through tokenization. Also there is a .03 per share dividend if you in by Oct. 30 and payble Dec. 2. See 8K i posted earlier. By last 3 calls all did well over 100% with $SCNX doing 350% and $TOVX well over 200%
0 · Reply